Cancer Family
Sarcoma
CI-CAN-00000344SARExplore in graph →
635 active trials17 approved drugs182 evidence items
- NCIt
- C9118
- OncoTree
- SARCNOS
- DOID
- 1115
- MeSH
- D012509
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000344SARExplore in graph →
Clinical trials
2,688 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (367)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03132155 | QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma | terminated | Phase 2 | 8 | NantPharma, LLCINDUSTRY | 1 | May 24, 2024 | clinicaltrials |
| NCT04625907 | FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma(FaR-RMS) | recruiting | Phase 1 / Phase 2 | 1,672 | University of BirminghamOTHER | 20 | May 23, 2024 | clinicaltrials |
| NCT05955105 | A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 200 | Innolake BiopharmINDUSTRY | 1 | May 21, 2024 | clinicaltrials |
| NCT01459484 | ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic Osteosarcoma(ISG/OS-2) | completed | Phase 2 | 225 | Italian Sarcoma GroupNETWORK | 1 | May 20, 2024 | clinicaltrials |
| NCT04480502 | ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma(ENVASARC) | unknown | Phase 2 | 207 | Tracon Pharmaceuticals Inc.INDUSTRY | 2 | May 17, 2024 | clinicaltrials |
| NCT05396118 | Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients | unknown | Phase 2 | 15 | Rigshospitalet, DenmarkOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT02624388 | Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)(UVA-Gen001) | terminated | Phase 2 | 4 | University of VirginiaOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT03993106 | A Study of sEphB4-HSA in Kaposi Sarcoma | unknown | Phase 2 | 65 | Vasgene Therapeutics, IncINDUSTRY | 1 | May 2, 2024 | clinicaltrials |
| NCT04742959 | Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 203 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Apr 26, 2024 | clinicaltrials |
| NCT06384248 | Phase II Clinical Study of LTC004 in Patients With Advanced Sarcoma | unknown | Phase 1 / Phase 2 | 30 | LetolabINDUSTRY | 0 | Apr 25, 2024 | clinicaltrials |
| NCT05926492 | A Clinical Study of Surufatinib Combined With Chemotherapy as Neoadjuvant Treatment in Osteosarcoma | unknown | Phase 2 | 160 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT02340884 | A Pilot RCT of the PRISM Intervention for AYAs With Cancer | completed | Phase 2 | 92 | Seattle Children's HospitalOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT00445965 | Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer | completed | Phase 2 | 78 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT05057130 | Neoadjuvant Combination of Doxorubicin, Cisplatin and Methotrexate in Patients Aged 24-40 Years With Primary Bone Tumors | unknown | Phase 2 / Phase 3 | 50 | Blokhin's Russian Cancer Research CenterOTHER | 1 | Apr 1, 2024 | clinicaltrials |
| NCT01386619 | NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) | completed | Phase 1 / Phase 2 | 15 | University Hospital, Basel, SwitzerlandOTHER | 2 | Mar 19, 2024 | clinicaltrials |
| NCT00019188 | Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma | completed | Phase 1 / Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT03711279 | A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue Sarcoma | terminated | Phase 2 | 99 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 29, 2024 | clinicaltrials |
| NCT03012620 | Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types(AcSé) | completed | Phase 2 | 334 | UNICANCEROTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT05189483 | Albumin-bound Paclitaxel Plus Camrelizumab for Advanced Soft Tissue Sarcoma. | unknown | Phase 2 | 40 | Henan Cancer HospitalOTHER_GOV | 1 | Feb 7, 2024 | clinicaltrials |
| NCT04274023 | Study on TSR-042 in Advanced Clear Cell Sarcoma(ACCeSs) | terminated | Phase 2 | 3 | Italian Sarcoma GroupNETWORK | 1 | Feb 1, 2024 | clinicaltrials |
| NCT03242382 | Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression.(PalboSarc) | unknown | Phase 2 | 40 | Grupo Espanol de Investigacion en SarcomasOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT02470091 | Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma | completed | Phase 2 | 56 | Children's Oncology GroupNETWORK | 3 | Jan 22, 2024 | clinicaltrials |
| NCT05262101 | Clinical Trial of TQB2858 Injection in the Treatment of Advanced High-grade Sarcoma | terminated | Phase 2 | 7 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 22, 2024 | clinicaltrials |
| NCT06217003 | Trilaciclib Combined With Chemotherapy for Perioperative Treatment of Osteosarcoma | unknown | Phase 2 | 20 | The First Affiliated Hospital of Xinxiang Medical CollegeOTHER | 1 | Jan 22, 2024 | clinicaltrials |
| NCT05154630 | Study on Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignant Tumors | terminated | Phase 1 / Phase 2 | 8 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jan 18, 2024 | clinicaltrials |
| NCT03422679 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | terminated | Phase 1 / Phase 2 | 79 | Cellestia Biotech AGINDUSTRY | 6 | Jan 16, 2024 | clinicaltrials |
| NCT01755195 | Cabozantinib for Adults With Advanced Soft Tissue Sarcoma | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Jan 3, 2024 | clinicaltrials |
| NCT04589754 | Adriamycin and Ifosfamide Combined With Sintilimab | unknown | Phase 2 | 176 | Sun Yat-sen UniversityOTHER | 1 | Jan 2, 2024 | clinicaltrials |
| NCT01336803 | Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI(Osteosarcoma) | completed | Phase 2 | 32 | Heike E Daldrup-LinkOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT04889742 | Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors(HETERERO) | not yet recruiting | Phase 2 | 110 | Charite University, Berlin, GermanyOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT04118166 | Ipilimumab + Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma | completed | Phase 2 | 30 | Kristen GanjooOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT05116683 | ATX-101 in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma(ATX-101) | terminated | Phase 2 | 4 | Benjamin IzarOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT03458728 | Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients | terminated | Phase 1 / Phase 2 | 31 | BayerINDUSTRY | 1 | Dec 4, 2023 | clinicaltrials |
| NCT04518124 | Propranolol in Angiosarcoma | completed | Phase 2 | 14 | The Netherlands Cancer InstituteOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT03056001 | Safety, Tolerability, and Efficacy of Doxorubicin and Pembrolizumab for Sarcoma | completed | Phase 2 | 30 | Wake Forest University Health SciencesOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT04365660 | 18F-FTC-146 PET/CT in Newly-Diagnosed Osteosarcoma | terminated | Phase 2 | 1 | Davidzon, Guido, M.D.OTHER | 1 | Nov 14, 2023 | clinicaltrials |
| NCT06125171 | Tucidinostat Plus Apatinib for Advanced Osteosarcoma | unknown | Phase 2 | 46 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Nov 9, 2023 | clinicaltrials |
| NCT02048371 | SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes | completed | Phase 2 | 131 | Sarcoma Alliance for Research through CollaborationOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT02584309 | Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma | completed | Phase 2 | 73 | Washington University School of MedicineOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT05094804 | A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents | unknown | Phase 1 / Phase 2 | 172 | OncoResponse, Inc.INDUSTRY | 1 | Nov 2, 2023 | clinicaltrials |
| NCT06114225 | Pulmonary Resectable Osteosarcoma Treated by Metastasectomy and Pre-operative Immunotherapy and Stereotactic Body Radiotherapy (PROMIS): a Prospective Clinical Trial(PROMIS) | recruiting | Phase 2 | 43 | Ruijin HospitalOTHER | 1 | Nov 2, 2023 | clinicaltrials |
| NCT03742193 | Pulmonary Resectable Metastases of Osteosarcoma With Anti-angiogenics and CHemotherapy(PROACH) | unknown | Phase 2 | 43 | Ruijin HospitalOTHER | 1 | Nov 1, 2023 | clinicaltrials |
| NCT00019968 | Isolated Limb Perfusion of Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Soft Tissue Sarcoma of the Arm or Leg | completed | Phase 2 | — | National Institutes of Health Clinical Center (CC)NIH | 0 | Oct 31, 2023 | clinicaltrials |
| NCT06074692 | PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA)(PRIMA) | recruiting | Phase 2 | 86 | Ruijin HospitalOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT02484443 | Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 5 | Oct 26, 2023 | clinicaltrials |
| NCT03063632 | Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma | completed | Phase 2 | 28 | National Cancer Institute (NCI)NIH | 1 | Oct 25, 2023 | clinicaltrials |
| NCT02304458 | Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas | completed | Phase 1 / Phase 2 | 140 | National Cancer Institute (NCI)NIH | 2 | Oct 17, 2023 | clinicaltrials |
| NCT02500797 | Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery | completed | Phase 2 | 164 | National Cancer Institute (NCI)NIH | 1 | Oct 17, 2023 | clinicaltrials |
| NCT03420014 | Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA)(FIBROSARC US) | unknown | Phase 2 | 114 | Philogen S.p.A.INDUSTRY | 1 | Oct 10, 2023 | clinicaltrials |
| NCT05329792 | L19IL2/L19TNF in Skin Cancer Patients(IntriNSiC) | unknown | Phase 2 | 70 | Philogen S.p.A.INDUSTRY | 3 | Oct 6, 2023 | clinicaltrials |
Data updated 23 days agoSource updated May 24, 2024source: clinicaltrials